Liang Cheng: SRC enhanced cisplatin resistance in bladder cancer
Liang Cheng, Professor and Vice Chair for Translational Research at The Warren Alpert Medical School of Brown University, shared an article by Yuwen Gong on LinkedIn:
“Happy Friday!
I am pleased to share our latest research, now published in the January issue of Nature Communications Biology CommsBio.
It’s a great honor to be part of this study!
Key Points:
- Overactivation of SRC drives cisplatin resistance in bladder cancer by enhancing glycolysis & the pentose phosphate pathway, shielding cancer cells from DNA damage.
- The SRC inhibitor eCF506 reverses resistance & boosts cisplatin sensitivity in vitro & in PDX models.
- Targeting SRC presents a promising strategy to enhance chemotherapy outcomes in bladder cancer.
Read the full study here.”
Authors: Yuwen Gong, et al.
Liang Cheng is a Professor and Vice Chair for Translational Research at The Warren Alpert Medical School of Brown University. He serves as the Director of Anatomic Pathology and Molecular Pathology at Lifespan Academic Medical Center. His research is focused on translational studies of genitourinary cancers and the molecular diagnostics of solid tumors.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023